Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, announced a strategic development partnership.

April 27, 2022 — Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, announced a strategic development partnership. The agreement brings together Verily’s cutting edge artificial intelligence (AI) algorithms with Lumea’s comprehensive end-to-end digital pathology platform with the objective to develop products which can diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.

According to the National Cancer Institute (NCI), in 2021 nearly 250,000 Americans were diagnosed with prostate cancer, and it is the second most common cause of cancer death among men in the country. New approaches in research and prostate cancer diagnosis and detection at an earlier stage are critical to improve mortality.  Currently, the Gleason grading system allows pathologists to analyze tissue growth patterns and aggressiveness, and new research has shown AI systems may help provide more accurate and optimal outcomes.  

Verily has developed AI systems for digital pathology to reduce variability and maximize insights from biopsy tissue samples.  This novel approach enables a new way to understand cancer by eliminating variability, generating more information with less tissue and providing advanced computation to empower both researchers and clinicians.

The Verily-Lumea collaboration goal will be to accomplish the following: 

  • Utilize Lumea’s digital pathology platform and extensive database of pathology cases to enable Verily to validate its Gleason algorithms for prostate cancer developed in partnership with Google Health
  • Integrate Verily’s algorithms into Lumea’s digital pathology platform. Pathologists will then have access to Verily’s AI to assist in identifying and grading prostate cancer within their existing digital workflow

“Verily’s Digital Pathology technologies have the promise to provide more efficient and valuable techniques to democratize access to precision oncology” said Jessica Mega, MD, MPH, Verily Chief Medical & Scientific Officer, Co-Founder.  “Lumea’s integrated digital pathology solution was the ideal technology platform for us to validate our artificial intelligence method to improve cancer detection and grading.” 

“Partnering with Verily will give Lumea’s customers access to world class AI without having to leave their workflow for another system or viewer. Verily’s algorithms will assist pathologists in both identifying and grading prostate cancer. These technology solutions will elevate patient care by giving physicians advanced tools to improve cancer diagnosis,” said John Wirthlin, Lumea CEO. 

For more information: www.lumea.net

Find more on digital pathology here


Related Content

News | PACS

November 28, 2022 — At this week’s Radiological Society of North America (RSNA) annual meeting (November 27 – December 1 ...

Time November 28, 2022
arrow
News | Mammography

November 28, 2022 — The Radiological Society of North America (RSNA) has announced the launch of the RSNA Screening ...

Time November 28, 2022
arrow
News | Artificial Intelligence

November 28, 2022 — Flywheel, a leading data management platform for biomedical research and collaboration, is creating ...

Time November 28, 2022
arrow
News | RSNA | By Christine Book

November 27, 2022 — Among dozens of technical exhibit visits, informative discussions, and captivating Plenary Session ...

Time November 27, 2022
arrow
News | RSNA

November 27, 2022— Royal Philips, a global leader in health technology, today announces its portfolio of smart ...

Time November 27, 2022
arrow
News | Contrast Media

November 26, 2022 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a ...

Time November 26, 2022
arrow
News | Artificial Intelligence

November 21, 2022 — The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now provides clinicians with key ...

Time November 21, 2022
arrow
Feature | RSNA | By Alan Stoddart

Top 10 Predictions for RSNA 2022 was published as an infographic as part of Signify Research's Premium Insights service ...

Time November 17, 2022
arrow
News | Artificial Intelligence

November 16, 2022 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Time November 17, 2022
arrow
News | Information Technology

November 14, 2022 — Med-tech startup Axial3D has announced the closing of a $15 million investment round led by a ...

Time November 14, 2022
arrow
Subscribe Now